Oncology
6th Annual Gulf-Atlantic Veterinary Conference
Chad Johannes, DVM, DACVIM (SAIM, Oncology)
Iowa State University
Toceranib phosphate (Palladia®) is a multireceptor tyrosine kinase inhibitor approved by the FDA Center for Veterinary Medicine in 2009 and labeled for the treatment of dogs with recurrent cutaneous Patnaik grade II or III mast cell tumors. A number of subsequent studies have helped to further define the best clinical use of this powerful therapeutic, including utility in many other types of cancer. Awareness of the most current information on Palladia can help guide decisions regarding which cancer patients it may benefit in your practice. This session summarizes key practical information regarding Palladia, including: mechanism of action, indication, potential adverse events, dosing/administration, and clinical data and utility (including case examples).